Literature DB >> 8702924

Determination of the amino acid residue involved in [3H]beta-funaltrexamine covalent binding in the cloned rat mu-opioid receptor.

C Chen1, J Yin, J K Riel, R L DesJarlais, L F Raveglia, J Zhu, L Y Liu-Chen.   

Abstract

We previously demonstrated that [3H]beta-funaltrexamine ([3H]beta-FNA) labeled the rat mu opioid receptor expressed in Chinese hamster ovary cells with high specificity, and [3H]beta-FNA-labeled receptors migrated as one broad band with a mass of 80 kDa. In this study, we determined the region and then the amino acid residue of the mu receptor involved in the covalent binding of [3H]beta-FNA. [3H]beta-FNA-labeled receptors were solubilized and purified to approximately 10% purity by immunoaffinity chromatography with antibodies against a C-terminal domain peptide. The site of covalent bond formation was determined to be within Ala206-Met243 by CNBr cleavage of partially purified labeled mu receptors and determinations of sizes of labeled receptor fragments. The amino acid residue of beta-FNA covalent incorporation was then determined by site-directed mutagenesis studies within this region. Mutation of Lys233 to Ala, Arg, His, and Leu completely eliminated covalent binding of [3H]beta-FNA, although these mutants bound beta-FNA with high affinity. Mutations of other amino acid residues did not affect covalent binding of [3H]beta-FNA. These results indicate that [3H]beta-FNA binds covalently to Lys233. Since [3H]beta-FNA is a rigid molecule, the information will be very useful for molecular modeling of interaction between morphinans and the mu receptor.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8702924     DOI: 10.1074/jbc.271.35.21422

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  20 in total

Review 1.  Homology modeling of opioid receptor-ligand complexes using experimental constraints.

Authors:  Irina D Pogozheva; Magdalena J Przydzial; Henry I Mosberg
Journal:  AAPS J       Date:  2005-10-05       Impact factor: 4.009

Review 2.  Molecular recognition of opioid receptor ligands.

Authors:  Brian E Kane; Bengt Svensson; David M Ferguson
Journal:  AAPS J       Date:  2006-03-10       Impact factor: 4.009

3.  The opioid antagonist, β-funaltrexamine, inhibits NF-κB signaling and chemokine expression in human astrocytes and in mice.

Authors:  Randall L Davis; Subhas Das; J Thomas Curtis; Craig W Stevens
Journal:  Eur J Pharmacol       Date:  2015-05-22       Impact factor: 4.432

4.  Consensus 3D model of μ-opioid receptor ligand efficacy based on a quantitative Conformationally Sampled Pharmacophore.

Authors:  Jihyun Shim; Andrew Coop; Alexander D MacKerell
Journal:  J Phys Chem B       Date:  2011-05-12       Impact factor: 2.991

5.  Characterization of functional μ opioid receptor turnover in rat locus coeruleus: an electrophysiological and immunocytochemical study.

Authors:  María Carmen Medrano; María Teresa Santamarta; Patricia Pablos; Zigor Aira; Itsaso Buesa; Jon Jatsu Azkue; Aitziber Mendiguren; Joseba Pineda
Journal:  Br J Pharmacol       Date:  2017-07-07       Impact factor: 8.739

6.  Dual labeled peptides as tools to study receptors: nanomolar affinity derivatives of TIPP (Tyr-Tic-Phe-Phe) containing an affinity label and biotin as probes of delta opioid receptors.

Authors:  Jane V Aldrich; Vivek Kumar; Thomas F Murray; Wei Guang; Jia Bei Wang
Journal:  Bioconjug Chem       Date:  2009-02       Impact factor: 4.774

7.  K303⁶·⁵⁸ in the μ opioid (MOP) receptor is important in conferring selectivity for covalent binding of β-funaltrexamine (β-FNA).

Authors:  Kelly M DiMattio; Chongguang Chen; Lei Shi; Lee-Yuan Liu-Chen
Journal:  Eur J Pharmacol       Date:  2014-12-04       Impact factor: 4.432

8.  Brain region-specific N-glycosylation and lipid rafts association of the rat mu opioid receptor.

Authors:  Peng Huang; Chongguang Chen; Wei Xu; Su-In Yoon; Ellen M Unterwald; John E Pintar; Yulin Wang; Parkson Lee-Gau Chong; Lee-Yuan Liu-Chen
Journal:  Biochem Biophys Res Commun       Date:  2007-10-31       Impact factor: 3.575

9.  Glial-restricted precursors: patterns of expression of opioid receptors and relationship to human immunodeficiency virus-1 Tat and morphine susceptibility in vitro.

Authors:  S K Buch; V K Khurdayan; S E Lutz; P E Knapp; N El-Hage; K F Hauser
Journal:  Neuroscience       Date:  2007-05-02       Impact factor: 3.590

10.  Discovery of dermorphin-based affinity labels with subnanomolar affinity for mu opioid receptors.

Authors:  Bhaswati Sinha; Zhengyu Cao; Thomas F Murray; Jane V Aldrich
Journal:  J Med Chem       Date:  2009-12-10       Impact factor: 7.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.